Results 361 to 370 of about 1,045,421 (416)

Initial Use Experience of Durvalumab Plus Gemcitabine and Cisplatin for Advanced Biliary Tract Cancer in a Japanese Territory Center. [PDF]

Cancers (Basel)
Shionoya K, Sofuni A, Mukai S, Yamauchi Y, Tsuchiya T, Tanaka R, Tonozuka R, Yamamoto K, Nagai K, Matsunami Y, Kojima H, Minami H, Hirakawa N, Zhan Q, Itoi T.   +14 more
europepmc   +1 more source

Antibody-Drug Conjugates and Their Potential in the Treatment of Patients with Biliary Tract Cancer. [PDF]

Cancers (Basel)
Alexander S, Aleem U, Jacobs T, Frizziero M, Foy V, Hubner RA, McNamara MG.   +6 more
europepmc   +1 more source

Biliary tract cancer [PDF]

The Lancet, 2021
Biliary tract cancers, including intrahepatic, perihilar, and distal cholangiocarcinoma as well as gallbladder cancer, are low-incidence malignancies in most high-income countries, but represent a major health problem in endemic areas; moreover, the incidence of intrahepatic cholangiocarcinoma is rising globally. Surgery is the cornerstone of cure; the
R. Katie Kelley, Juan W. Valle, Juan W. Valle, Do Youn Oh, Andrew X. Zhu, Bruno Nervi   +5 more
openaire   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.

NEJM Evidence, 2022
Durvalumab Combination for Biliary Tract CancerThis trial randomly assigned patients with previously untreated locally advanced or metastatic biliary tract cancer to receive durvalumab or placebo in combination with gemcitabine plus cisplatin.
D. Oh, A. Ruth He, S. Qin, Li‐Tzong Chen, T. Okusaka, A. Vogel, J. W. Kim, T. Suksombooncharoen, Myung Ah Lee, Masayuki Kitano, H. Burris, M. Bouattour, S. Tanasanvimon, M. McNamara, R. Zaucha, A. Avallone, Benjamin Tan, J. Cundom, Choong-kun Lee, Hidenori Takahashi, M. Ikeda, Jen‐Shi Chen, Julie Wang, M. Makowsky, N. Rokutanda, P. He, J. Kurland, G. Cohen, J. Valle   +28 more
semanticscholar   +1 more source

Increasing gallstone disease prevalence and associations with gallbladder and biliary tract mortality in the US

Hepatology, 2023
Background and Aims: We examined gallbladder and biliary tract mortality predictors in the US National Health and Nutrition Examination Survey (NHANES), 1988-1994, with 31 years of linked mortality data, and gallstone disease prevalence trends and ...
A. Unalp-arida, C. Ruhl
semanticscholar   +1 more source

Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer

Expert Review of Gastroenterology & Hepatology, 2021
Introduction: Unfortunately, potentially curative surgical resection is possible in approximately the 25% of biliary tract cancer (BTC) patients at diagnosis, and even following radical surgery, relapse rates remain high.
A. Rizzo, G. Brandi
semanticscholar   +1 more source

Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death‐Ligand 1 Blockade Responses

Hepatology, 2021
Biliary tract cancer (BTC) exhibits diverse molecular characteristics. However, reliable biomarkers that predict therapeutic responses are yet to be discovered.
Jihoon G. Yoon, Min Hwan Kim, M. Jang, Hoguen Kim, H. Hwang, C. Kang, Woo-Jung Lee, B. Kang, Choong-kun Lee, Min Goo Lee, H. Chung, Hye Jin Choi, Y. N. Park   +12 more
semanticscholar   +1 more source